


FIG. 1




FIG. 2




FIG. 3




FIG. 4



ADRB2
Luc 234–550
X
Luc 2–233
Arrestin
TEV
RLU
7000
6000
5000
4000
3000
2000
1000
0
ADRB2–luc234–S–233
ADRB2–luc234–S–233+Arr–TEV
ADRB2–luc234–R–233
ADRB2–luc234–R–233+Arr–TEV
ADRB2–luc234–V–233
ADRB2–luc234–V–233+Arr–TEV

FIG. 5




FIG. 6



RLU
30000
20000
10000
0
-12
-11
-10
-9
-8
-7
-6
-5
-4
log[Isoproterenol], M
RLU %
110
100
90
80
70
60
50
40
30
20
10
0
-11
-10
-9
-8
-7
-6
-5
-4
log[Isoproterenol], M

FIG. 7



ADRB2
TEV
Arrestin 2
Luc 234–550
x
Luc 2–233
RLU
10000
8000
6000
4000
2000
0
5 hours incubation
1 hour incubation
−11
−10
−9
−8
−7
−6
−5
−4
−3
log[Isoproterenol], M

FIG. 8



RLU
50000
40000
30000
20000
10000
0
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4
log[Isoproterenol], M
RLU
4500
4000
3500
3000
2500
2000
1500
1000
500
0
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4
log[Isoproterenol], M

FIG. 9



Agonist–isoproterenol
Partial agonist
Antagonist + isoproterenol
Antagonist
S1P–endogenous agonist
RLU
55000
50000
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
-13
-12
-11
-10
-9
-8
-7
-6
-5
-4
log[cpd], M

FIG. 10



8-AVP (agonist)
RLU
60000
50000
40000
30000
20000
10000
0
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4
log[8-AVP] M
RLU
40000
30000
20000
10000
0
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4
Log[agonist], M

FIG. 11



Propranolol
Isoproterenol
Propranolol+Isoproterenol(0.2uM)
RLU
log[cpd], M
Isoproterenol (agonist)
inverse agonist
inverse agonist + isop
RLU
log[cpd], M

FIG. 12




RLU
40000
30000
20000
10000
0
-13
-12
-11
-10
-9
-8
-7
-6
-5
-4
log[SR121463], M
Log [agonist], M

FIG. 13


15000
10000
5000
0
RLU
-13
-12
-11
-10
-9
-8
-7
-6
-5
-4
log[Isoproterenol], M



CMV
ADRB2
GS
Luc234-550
xx
Luc2-456
Arrestin 2
TEV

FIG. 14




FIG. 15




FIG. 16




FIG. 17